
NYSE:MMM
This summary was created by AI, based on 2 opinions in the last 12 months.
The recent reviews on 3M Co. (MMM-N) present a divided perspective on its outlook. One expert points out optimism surrounding the company's new CEO, suggesting a turnaround that could potentially enhance stock performance ahead of the upcoming earnings report. This indicates a belief in the company's ability to recover and grow. Conversely, another review advises taking profits, implying that while the stock may have cleared some obstacles, it now represents a lower-growth opportunity within the multi-industrial sector. This critic favors investing in more robust industrial alternatives like Honeywell or the various components of the former United Technologies, hinting at a belief that there are better prospects elsewhere. Therefore, the consensus reflects a cautious view on 3M’s growth trajectory, suggesting a wait-and-see approach as investors analyze the company’s future performance against its competitors in the industry.
Had a little bit of difficulty. Seem to have been 1 step forward and 2 steps back over the last several years. This has happened to a lot of the industrial conglomerates because the global economy has not been steady. Over the last couple of quarters they have got it together a little bit and most of their divisions are moving in concert and doing fairly well. Doesn’t feel it is overpriced at 14X earnings. Decent dividend.
J.P. Morgan did a list of 15 stocks whose free cash flow yield was fairly substantial and have had great resilience in down markets and have outperformed markets on the upside. This was one of them. This is an international conglomerate including healthcare. Thought it was a bit on the expensive side but based on the report by J.P. Morgan, he is going to have a look at this one.
Feels it is cheap right now but is probably likely to stay cheap for the next little while. Global growth which is not overly robust, doesn’t favour the space that this company is in. He likes their broad geographic exposure. 40%-50% of their revenues are earned outside of the US with quite a bit in more rapidly growing emerging markets. You’ll have to be patient with it. 2.5% dividend.